Fundraising FoxAvoro Capital Advisors
Crossover fundActively deployingNew York · Series A–Late Stage · 22 people tracked
Find your way into Avoro Capital Advisors
Sign up to see every warm intro you have to Avoro Capital Advisors
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avoro Capital Advisors team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Avoro Capital Advisors seeks scientific breakthroughs with the potential to address unmet medical needs, driven by intellectual curiosity. The firm aims to identify unique or mispriced investment opportunities, analyzing complex situations and supporting companies with both financial and intellectual resources across the lifecycle of an investment. It emphasizes disciplined risk management, evaluating macro and company-specific risks, and may employ tactical and fundamental hedges within its portfolio construction while carefully weighing position sizing and liquidity considerations.
Source: firm website, verified Oct 13, 2026.
Team · 22 people
from the firm's website & public directories
Managing Partner and Portfolio Manager of Avoro Capital with over 25 years in the biopharmaceutical industry across research, consulting, investing, and board leadership. He holds a physics master's from Ludwig-Maximilians-University and a PhD from Cornell, previously worked at Booz Allen Hamilton, Bernstein Value Equities, and Sio Capital, and served as Executive Chairman of Immunomedics until its $21B acquisition by Gilead.
Investment Partner at Avoro Ventures with 15 years of healthcare experience across venture capital, consulting, and corporate development. He was previously a Managing Director at Arix Bioscience and a Principal at Longitude Capital, and earlier worked at BCG, Gilead Sciences, and Genentech.
Partner, COO, and CCO responsible for operational, financial, and compliance infrastructure across Avoro Capital since 2014. He previously spent 11 years at HSBC as Regional Head of the Americas for securities services and was a VP at Sanford C. Bernstein.
Investment Partner at Avoro Ventures since 2022 with 15 years of healthcare experience across venture capital, public equity investing, and academic research. Previously a Principal at Amzak Health and a biotech equity research analyst at Goldman Sachs, she holds a microbiology PhD from NYU and a biochemistry degree from Cornell.
Director at Avoro Capital since 2019, focused on evaluating mid-to-late stage biotechnology investments. He holds a bioengineering degree from Penn and an MD/PhD from Harvard Medical School, with a PhD in CRISPR-based gene therapy for sickle cell disease.
Associate focused on biopharma and late-stage commercial biotech opportunities, joining Avoro Capital in 2025. He previously worked in equity research at Piper Sandler and JP Morgan and as a consultant at RxC International, holding a biomedical sciences degree from UCL.
Deputy Chief Compliance Officer administering Avoro's compliance program since 2020. He was previously CCO at Centenus Global Management and a compliance officer at Citadel, Visium, and Goldman Sachs, and holds a JD from New York Law School.
Office Manager and Executive Assistant who joined Avoro in 2023, previously executive assistant to CEOs at Hunter Point Capital and TigerRisk Partners, with an accounting degree from Southern Utah University.
Associate focused on evaluating biotechnology investments, joining Avoro in 2025. He holds a history and science degree from Harvard College and an MD and MPH from Harvard, with over 20 first-author medical publications.
Hedge fund controller with over 15 years of accounting and operations experience, joining Avoro Capital in 2016 after nine years at Matlin Patterson Global Advisors and earlier work at PwC. She holds a finance and accounting degree from NYU Stern and is a New York CPA.
Associate at Avoro Ventures since 2024, holding a PhD in Cellular and Molecular Medicine from Johns Hopkins and a neuroscience degree from Rochester. She previously interned at Catalio Capital Management conducting biotech investment diligence.
Manager of Investor Relations and Marketing who joined Avoro in 2022, previously a business development associate at Suvretta Capital and an associate at Blackstone's Hedge Fund Solutions Group. She holds accounting degrees from the University of Florida.
Head of Investor Relations and Marketing since 2024, leading Avoro's IR and business development. She was previously a Managing Director at Jennison Associates and Head of Investor Relations at Gotham Asset Management, and began her career at Goldman Sachs Asset Management.
Receptionist and Executive Assistant with a background in recruiting and education, holding a communication studies degree from James Madison University. She previously administered at Vivvi Early Learning.
CFO of Avoro Capital since 2024, previously CFO and Chief Accounting Officer at Bridger Capital and earlier in PwC's Asset Management Practice. He holds an accounting degree and finance MBA from Fordham and is a New York CPA.
Trader with over 10 years of trading and operations experience, joining Avoro Capital in 2019 after being Head Trader at Jafra Capital Management and a trader at Jericho Capital. He holds a political science degree from the University of Rochester.
Associate focused on evaluating biotechnology investments, holding a computer science degree from Williams and a PhD in Computational Biology from MIT. She previously worked at Norwest Venture Partners on biotech and medtech investments.
Senior Analyst focused on quantitative analysis and portfolio analytics, joining Avoro Capital in 2019 after working as a trader/analyst at Apex Capital Holdings. He holds a math and economics degree from Tufts.
What they invest in
from 64 of 79 portfolio companiesBiotech ×62Healthtech ×47Medical Devices ×25Deep Tech ×10Digital Health ×5Longevity ×4AI & Machine Learning ×3Cloud Computing ×1
HQs:United States×45Switzerland×1Denmark×1United Kingdom×1Netherlands×1
Who they back
founder profiles across 30 portfolio companiesFounding team size:solo founder×122 founders×103 founders×24+ founders×6
Where their founders studiedfrom 21 founders with education data
University of California, Berkeley ×4Harvard University ×3Princeton University ×3Brown University ×2Columbia University ×2Harvard Medical School ×2Imperial College London ×2
What their founders studiedfrom 21 founders with field-of-study data
Life Sciences ×11Chemistry ×8Engineering ×2Finance & Accounting ×2Medicine ×2
Where their founders worked beforefrom 24 founders with career history
Atlas Venture ×4GNF ×2
13 founders hold a PhD · 3 hold an MBA (of 22 with degree data)
Investments · 79 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22022 · 12021 · 42020 · 12019 · 12018 · 22017 · 52016 · 12015 · 42014 · 42012 · 229 dated
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US
James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in
Co-investorsEight Roads VenturesF-Prime CapitalForesite CapitalNew Enterprise Associates (NEA)Ridgeback Capital
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsForesite CapitalTPGVida VenturesGilead Sciences
Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.
BiotechHealthtechCambridge, US
Justin Klee(Director)inJoshua Cohen(Founder)in
BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)
Co-investorsAlpha Wave GlobalALS Investment FundBain Capital Life Sciences
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsQuan CapitalRA CapitalSR One Capital ManagementWellington ManagementWestRiver Group
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyHealthCapNovo HoldingsSofinnova PartnersRA Capital
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureEcoR1 CapitalForesite CapitalOrbiMedRidgeback Capital+1 more
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
PINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersEcoR1 CapitalForesite CapitalNextech InvestOUP (Osage University Partners)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+7 more
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in
Co-investorsBay City CapitalForesite Capital
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalHBM PartnersNew Enterprise Associates (NEA)Versant VenturesAmzak HealthGV (Google Ventures)+4 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalLightspeed Venture PartnersRA CapitalWellington ManagementBiotechnology Value Fund+2 more
Outlook Therapeutics develops ophthalmic therapies for retinal diseases, including anti-VEGF treatments for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion.
BiotechHealthtechMedical DevicesIselin, US
Pankaj Mohan(Executive Officer, Director)Lawrence A. Kenyon(Executive Officer, Director)inJeff Evanson(Executive Officer)in
BoardFaisal G. Sukhtian(Director)Yezan Haddadin(Director)Andong Huang(Director)
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
BoardNicholas G. Galakatos(Director)in
Co-investorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstoneClarus Ventures+6 more
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Brett Staahl(Founder)
Co-investorsAndreessen HorowitzOrbiMedMenlo VenturesRA CapitalWellington Management
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundBioBritDelos CapitalEcoR1 CapitalForesite Capital+6 more
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies in areas such as metabolic and endocrine disorders.
BiotechHealthtechLongevitySan Diego, US
Brian Lian(President, CEO & Director (Founder))inMichael Morneau(Chief Financial Officer)Dr. Lian(President & Chief Executive Officer, Director)Stephen W. Webster(Director)Matthew W. Foehr(Director)Brian Lian, Ph.D.(President and Chief Executive Officer; founder of Viking Therapeutics)
Co-investorsLigand Pharmaceuticals
Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.
BiotechHealthtech
Ian Mortimer(President and Chief Executive Officer)inDarren Cline(Chief Commercial Officer)inAndrea DiFabio(Chief Legal Officer and Corporate Secretary)inJames Empfield(Executive Vice President, Drug Discovery)inTucker Kelly(Chief Financial Officer)inChris Kenney(Chief Medical Officer)in
Co-investorsArcher Capital GroupArcher Venture CapitalForesite CapitalNew Enterprise Associates (NEA)
Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.
BiotechHealthtechCambridge, US
Niranjan Kameswaran(Chief Executive Officer)inJessica Stromme(Chief Development Officer)inKelly Foster(Chief Scientific Officer)inStephen Huang(Senior Vice President, Head of Clinical Development)in
BoardSimon Read(Chairman of the Board and Independent Board Member)in
Co-investorsAtlas VentureMedicxi
Develops novel therapeutics in oncology and autoimmune diseases.
Co-investorsBioGeneration VenturesBOMFrazier Life Sciences
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsFrazier Life Sciences5AM VenturesSamsara BioCapitalVenrock Healthcare Capital PartnersVivo Capital
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsFountain Healthcare PartnersLongitude CapitalSignet Healthcare PartnersSofinnova Ventures
Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)John Crowley(Founder)William D. Baird, III(Executive Officer)
BoardCraig A. Wheeler(Director)Ted W. Love(Director)inMargaret G. McGlynn(Director)
Co-investorsCanaan PartnersFrazier Life SciencesNew Enterprise Associates (NEA)Prospect Venture Partners
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
BiotechCrestwood, US
Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in
BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)
Co-investorsEMBL VenturesEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta Ventures+1 more
The company develops therapies for people with severe autoimmune diseases.
BiotechHealthtechMedical Devices
Co-investorsBioGeneration VenturesHBM Healthcare InvestmentsMPM BioImpactPMVSeventure PartnersAescap Life Sciences+2 more
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalForesite CapitalRA CapitalSofinnova PartnersSofinnova Ventures
Assembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.
BiotechHealthtechMedical Devices
Jason Okazaki(Chief Executive Officer & President)inWilliam Delaney, PhD(Chief Scientific Officer)Anuj Gaggar, MD, PhD(Chief Medical Officer)
Co-investorsLongitude Capital
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalLongitude CapitalCatalio Capital Management, LPOrbiMedDigitalis VenturesOmega Funds
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)inMark E. Davis(Director)Troy Wilson(Executive Officer, Director)in
BoardTodd Brady(Director)Michael Martin PhD.(Director)
Co-investorsBrace PharmaF-Prime CapitalFrazier Life SciencesMoore Venture Partners
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.
BiotechHealthtechBaltimore, US
James N. Campbell(President, Chief Scientific Officer)inKerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in
Co-investorsCatalio Capital Management, LPEFung CapitalNew Enterprise Associates (NEA)Quan Capital6 Dimensions CapitalExome Asset Management
Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Co-investorsBain Capital Life SciencesThe Column GroupVenrockThird Rock Ventures
Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)
Co-investorsForesite CapitalOrbiMedRoche Venture Fund
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Co-investorsCLI VenturesKhosla VenturesNew Enterprise Associates (NEA)SR One Capital ManagementVersant VenturesWellington Management+2 more
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in
Co-investorsBay City CapitalForesite CapitalVantagePoint Capital PartnersAbingworth
Fennec Pharmaceuticals develops treatments for cisplatin-induced hearing loss, a side effect of cancer chemotherapy.
BiotechHealthtechMedical DevicesResearch Triangle Park, US
Krysia Lynes(Executive Officer)Rostislav Raykov(Executive Officer, Director)
BoardAdrian Haigh(Director)Steven Skolsky(Director)Chris Rallis(Director)Khalid Islam(Director)
Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.
South San Francisco, US
John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in
BoardKevin Starr(Director)inCharles Homcy, M.D.(Director)
Co-investorsAisling CapitalRA CapitalRidgeback CapitalThird Rock VenturesWellington Management
HedgeServ provides a cloud-based investor services platform for investment managers that automates fund administration tasks including investor onboarding, capital calls, distributions, and reporting.
Cloud ComputingFintechSaaSDallas, US
Co-investorsAquiline Technology GrowthGolub Growth
Amgen is a pioneer in biologic medicine development using living cells to create treatments for serious illnesses with limited existing options.
BiotechHealthtech
Co-investorsAtlas VentureNew Enterprise Associates (NEA)
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsEIR VenturesKurma PartnersPivotal Life SciencesRA CapitalSamsara BioCapitalSunstone Capital+3 more
Iovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsFrazier Life Sciences
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSRA Capital
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
BoardDan Janney(Director)
Co-investorsFrazier Life SciencesAlta Partners
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesDomain AssociatesFlare Capital Partners+1 more
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture Investments+3 more
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)inMark Throsby(Executive Officer)inHui Liu(Executive Officer)inJohn Crowley(Executive Officer)inL. Andres Sirulnik(Executive Officer)inLex Bakker(Executive Officer)in
Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova Ventures
Mirati develops investigational medicines and treatments for patients with multiple myeloma and other oncology indications.
BiotechHealthtechMedical Devices
Co-investorsBioBritBoxer Capital, LLCNextech InvestPappas Capital
ImmunityBio develops investigational immunotherapies that activate both innate and adaptive immune responses—stimulating NK cells, T cells, macrophages, and dendritic cells—to treat cancer and infectious diseases.
BiotechLongevityMedical Devices
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+6 more
Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies.
BiotechHealthtechMedical DevicesCambridge, US
Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inJames Porter, PhD(Chief Executive Officer)Alex Balcom(Chief Financial Officer)inChristopher Turner, MD(Chief Medical Officer)
Co-investorsBain Capital Life SciencesDeerfield Management CompanyViking GlobalWellington Management
Ottimo is a biotech company developing oncology and immuno-oncology therapeutics, including antibody-based cancer treatments.
BiotechHealthtech
Jonny Finlay(Founder and Chief Scientific Advisor)David Epstein(Chair & Chief Executive Officer)inMehdi Shahidi(Head of Development & Chief Medical Officer)Ling Zeng(General Counsel and EVP of Execution)inSpencer Fisk(Chief Technical and Quality Officer)
Co-investorsOrbiMedMedicxiSamsara BioCapitalJMI Equity
PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations.
BiotechHealthtechLongevityCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Co-Founder & Member, Scientific Advisory Board)David H. Mack(Co-Founder, President & CEO)Thomas Shenk(Co-Founder)Deepika Jalota(Chief Development Officer)
Co-investorsNextech InvestOUP (Osage University Partners)RA CapitalViking GlobalWellington ManagementOrbiMed
Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
Co-investorsF-Prime CapitalNew Enterprise Associates (NEA)Sanofi VenturesSofinnova Ventures
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)in
BoardRoderick Wong(Director)inNaveen Yalamanchi(Director)in
Co-investorsBroadview VenturesCivilization Ventures Management, LlcFrazier Life SciencesLifeSci Venture PartnersRTW Investments L.P.
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)
Co-investorsRoche Venture Fund
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Co-investorsAtlas VentureEcoR1 CapitalFrazier Life SciencesNextech InvestVida VenturesAbingworth+3 more
Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer.
BiotechHealthtechNew York, US
Ivan Bergstein, M.D.(Executive Officer, Director)
BoardRonald Bentsur(Director)
GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients.
BiotechHealthtechLondon, GB
Mary Lynne Hedley(Executive Officer, Director)Leon O. Moulder, Jr.(Executive Officer, Director)Jeffrey Hanke(Executive Officer)Joseph L. Farmer(Executive Officer)inGrant C. Bogle(Executive Officer)Martin H. Huber(Executive Officer)
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Pappas CapitalRidgeback Capital
Biotechnology company developing cellular therapies for organ transplantation and autoimmune disorders.
Co-investorsAnjostLongitude CapitalScion Life SciencesTCG CrossoverVivo CapitalQiming Venture Partners
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)
Co-investorsLongitude CapitalWellington ManagementFrazier Life SciencesHercules Capital, Inc.OrbiMed
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardJonathan Silverstein(Director)inBernard Davitian(Director)Uya Chuluunbaatar(Director)
Co-investorsOrbiMedOUP (Osage University Partners)Pontifax Venture CapitalCasdin CapitalOmega Funds
AI & Machine LearningBiotechHealthtech
Co-investorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)venBio PartnersJMI Equity
Viveve publishes evidence-based health guides covering six core topics—heart health, women's health, nutrition, hormones, sexual health, and aging—written without pseudoscience or supplement marketing.
Digital HealthHealthtechMedia & EntertainmentWellness & Fitness
Co-investors5AM Ventures
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersCardinal PartnersNextech InvestSoftBank Vision FundAlexandriaALTITUDE LIFE SCIENCE VENTURES+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Avadel PharmaceuticalsBellicumCatalyst BiosciencesDiceEndocyteGlobal BloodImmunomedicsIVERIC BioMyokardiaTherachonZealand PharmaZogenix
Exits · 26
17 IPOs · 9 acquisitions · showing 25AdaptimmuneOTC: ADAPYAllogene TherapeuticsNASDAQ: ALLOAmylyxNASDAQ: AMLXDesigntxNASDAQ: DSGNHemab TherapeuticsNASDAQ: COAGIntellia TherapeuticsNASDAQ: NTLAKura OncologyNASDAQ: KURAKymera TherapeuticsNASDAQ: KYMRMadrigalNASDAQ: MDGLMonte Rosa TherapeuticsNASDAQ: GLUEOlema PharmaceuticalsNASDAQ: OLMAOutlook TherapeuticsNASDAQ: OTLKPraxisNASDAQ: PRAXScribe TherapeuticsNASDAQ: SCTXSyndax PharmaceuticalsNASDAQ: SNDXViking TherapeuticsNASDAQ: VKTXXenon PharmaceuticalsNASDAQ: XENEApellis Pharmaceuticalsacq. by BiogenConstellation Pharmaacq. by NovartisGlobal Blood Therapeuticsacq. by PfizerHorizon Therapeuticsacq. by AmgenMyokardiaacq. by Bristol Myers SquibbProteostasis Therapeuticsacq. by Yumanity TherapeuticsVicebioacq. by SanofiVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companiesCRISPR · massbio.org · Sep 6, 2026
Whitehawk · prnewswire.com · Sep 2, 2026
Amylyx · biopharminternational.com · Aug 20, 2026
Outlook Therapeutics · visionmonday.com · Aug 17, 2026
Syndax Pharmaceuticals · aol.com · Aug 12, 2026
Praxis · marketbeat.com · Aug 6, 2026
Frequently asked questions
- How many investments has Avoro Capital Advisors made?
- Avoro Capital Advisors has 79 tracked investments, 26 of which have exited, including 3 dated in the last 24 months.
- What stage does Avoro Capital Advisors invest at?
- Avoro Capital Advisors invests at the Series A, Growth, Late Stage stages.
- What sectors does Avoro Capital Advisors focus on?
- Avoro Capital Advisors focuses on Biotech, Healthtech, Medical Devices.
- Where is Avoro Capital Advisors located?
- Avoro Capital Advisors is headquartered in New York, US.
- Who does Avoro Capital Advisors co-invest with?
- Avoro Capital Advisors most often shares deals with Foresite Capital, Sofinnova Ventures, Frazier Life Sciences, among 105 tracked co-investors.
Co-investors · 10
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Innovation Works is a nonprofit early-stage investor supporting the growth of Southwestern Pennsylvania's tech economy through venture funding, accelerator programs, and ecosystem support.
Riverfront Ventures is an early-stage venture capital fund based in Pittsburgh that invests in early-growth stage technology companies, serving as the venture capital arm of Innovation Works.
Pappas Capital is a life science-focused investment firm that funds and helps build companies developing next-generation products and technologies across the range of human disease.
Firms observed investing alongside Avoro Capital Advisors, from public investor directories. Shared companies are the overlap with Avoro Capital Advisors's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Kreos Capital is a growth debt provider financing high-growth technology and healthcare companies across Europe and Israel. Founded in 1998, it was acquired by BlackRock in August 2023 and now operates within BlackRock's Private Markets platform.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.